πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9149437

Method for treatment of solid pharmaceutical preparation prior to printing and solid pharm

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9149489

Inhibitors of glycolysis useful in the treatment of brain tumors

The Board of Regents of the University of Texas System Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9138479

Formulations for the treatment of diabetes

XERIS PHARMACEUTICALS, INC. Β· Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9139834

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesi

Arrowhead Research Corporation Β· Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9132138

Method for the treatment of multiple sclerosis

CASI Pharmaceuticals, Inc Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9132107

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Jazz Pharmaceuticals Ireland Limited Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9132174

Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)

Anchored RSK3 Inhibitors, LLC Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9127277

Methods and compositions for prevention or treatment of RSV infection

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9126941

Treatment of hyperproliferative disorders with diarylhydantoin compounds

The Regents of the University of California Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9121852

Carcinoma diagnosis and treatment, based on ODC1 genotype

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION Β· Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9120813

Oxadiazoanthracene compounds for the treatment of diabetes

VTV THERAPEUTICS LLC Β· Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9119884

LLP2A-bisphosphonate conjugates for osteoporosis treatment

The Regents of the University of California Β· Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9119863

Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal trac

The Regents of the University of California Β· Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9115371

Reduction of TGF beta signaling in myeloid cells in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9115120

Heterocyclic modulators of HIF activity for treatment of disease

The Board of Regents of the University of Texas System Β· Granted Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9114102

Method of inhibiting ABCG2 and related treatments

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9110064

Methods for diagnosis and treatment of endometrial cancer

The Regents of the University of California Β· Granted Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9107912

Methods for concomitant treatment of theophylline and febuxostat

Takeda Pharmaceuticals U.S.A., Inc. Β· Granted Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9107887

Combination of local and systemic immunomodulative therapies for enhanced treatment of can

Provectus Pharmaceuticals, Inc. Β· Granted Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9102626

Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9096499

Compounds for treatment of cell proliferative diseases

The Board of Regents of the University of Texas System Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9095579

Protection and treatment against influenza infection

The Regents of the University of California Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9089698

Method and apparatus for optogenetic treatment of blindness including retinitis pigmentosa

The Regents of the University of California Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9089531

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA co

The Regents of the University of California Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted